738 reports of this reaction
3.3% of all GRANISETRON HYDROCHLORIDE reports
#5 most reported adverse reaction
PYREXIA is the #5 most commonly reported adverse reaction for GRANISETRON HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 738 FDA adverse event reports linking GRANISETRON HYDROCHLORIDE to PYREXIA. This represents approximately 3.3% of all 22,079 adverse event reports for this drug.
Patients taking GRANISETRON HYDROCHLORIDE who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is moderately reported among GRANISETRON HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to pyrexia, the following adverse reactions have been reported for GRANISETRON HYDROCHLORIDE:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 738 FDA reports for GRANISETRON HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 3.3% of all adverse event reports for GRANISETRON HYDROCHLORIDE, making it a notable side effect.
If you experience pyrexia while taking GRANISETRON HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.